Healthcare

Few ASX health-tech companies have commanded as much investor attention in recent years as 4DMedical Ltd (ASX: 4DX). The Melbourne-headquartered respiratory diagnostics company has built a genuinely novel product, attracted partnerships with global giants, and expanded into the world's largest healthcare market. Yet recent …

Cyclopharm Limited (ASX:CYC), the ASX-listed nuclear medicine company behind the Technegas lung ventilation imaging platform, has experienced a period of share-price weakness that has attracted renewed investor scrutiny.

• Improving sentiment across the biotech sector has renewed investor interest.

• Investors are reassessing the company as its share price shows renewed strength.

The interest reflects more than a single company’s progress. Med-tech has periodically reasserted itself as a theme on the Australian market, buoyed by a handful of success stories that have shown how a well-executed device can scale globally. As sentiment toward the sector improves, …

The appeal is easy to understand. Radiopharma blends the diagnostic and therapeutic sides of cancer care in a way that resonates with a market hungry for differentiated science. When sentiment toward the theme runs warm, companies pursuing novel isotopes and delivery platforms tend to …

The interest is partly a sector story. When sentiment towards medical device names improves, smaller specialists with established niches and global reach tend to benefit from the broader warming. Compumedics, with its long-standing position in sleep diagnostics and brain monitoring, is among the local …